Actively Recruiting
TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors
Led by Beijing GoBroad Hospital · Updated on 2026-01-21
30
Participants Needed
2
Research Sites
97 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a single-arm, open-label, dose-escalation clinical trial designed to evaluate the safety, tolerability, expansion, and persistence of TC-G203 in patients with GPC3-positive recurrent or metastatic solid tumors who have progressed after prior therapies. The primary objective is to determine the maximum tolerated dose (MTD), with a secondary aim to assess preliminary clinical efficacy in solid tumors.
CONDITIONS
Official Title
TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must voluntarily provide written informed consent.
- Aged 18-75 years (inclusive).
- Life expectancy at least 12 weeks.
- ECOG performance status 0-1.
- Failed or unsuitable for standard therapy.
- At least one measurable lesion per RECIST 1.1.
- GPC3-positive tumor confirmed by immunohistochemistry.
- Adequate organ and bone marrow function.
- Effective contraception required for participants of childbearing potential.
- Adequate venous access for leukapheresis.
You will not qualify if you...
- Primary CNS malignancy or uncontrolled CNS metastases.
- Other malignancies within 5 years.
- Active autoimmune disease or history of autoimmune disease.
- Immunodeficiency, including HIV positivity.
- Bleeding disorders (inherited or acquired).
- Clinically significant cardiovascular disease.
- Active infection (including tuberculosis, hepatitis C, syphilis).
- Pregnant or breastfeeding women.
- Severe systemic or psychiatric illness.
- Prior cell or gene therapy.
- Severe drug hypersensitivity history.
- Investigator-assessed unsuitability for trial participation.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Beijing Gobroad Hospital
Beijing, Beijing Municipality, China, 100000
Actively Recruiting
2
GoBroad Healthcare Group
Beijing, Beijing Municipality, China, 102206
Not Yet Recruiting
Research Team
C
Changsong Qi
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here